



CSE : MYTC
Investor Presentation
November 2022

MyndTec

A Neuroscience Technology Company



Restoring Independence, One Step At A Time.

FORWARD LOOKING STATEMENTS




Disclaimer

This presentation (the "Presentation") of MyndTec Corp. (the "Company") is current as of May, 30, 2022, except as otherwise provided herein. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. An investment in the Company is speculative and involves substantial risk and is only suitable for investors that are able to bear the risk of losing their entire investment. All of the information contained in this Presentation is for preliminary discussion purposes only. Final terms and conditions may change without notice and are subject to further discussion and negotiations.

Certain statements in this Presentation may constitute forward-looking information within the meaning of applicable securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "expects," "believes," "anticipates," "budget," "scheduled," "estimates," "forecasts," "intends," "plans," and variations of such words and phrases, or by statements that certain actions, events or results "may," "will," "could," "would," or "might," "be taken," "occur," or "be achieved." Certain statements, beliefs and opinions in this Presentation (including those contained in graphs, tables and charts), which reflect the Company's or, as appropriate, the Company's managements' current expectations and projections about future events, constitute forward-looking information. Forward-looking information contained in this Presentation is based on certain assumptions regarding, among other things, expected growth, results of operations, performance, industry trends and growth opportunities.

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. The Company does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. Persons receiving or reviewing this Presentation should not rely upon it as a complete overview of the business of the Company and should rely on their own investigation and due diligence. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice. You should consult your tax or legal advisor about the information contained in this Presentation.

In this Presentation, and during the course of discussions related to the evaluation of any prospective investment in the Company (the "Purpose"), the Company may disclose certain information which it deems proprietary or confidential, and may include, discoveries, ideas, concepts, know-how, techniques, designs, specifications, drawings, blueprints, diagrams, flow charts, data, costs, prices, marketing plans, goals, sales figures, revenue, profits, and other technical, financial or business information respecting existing or planned product or service offerings, including products and services to be developed or marketed by the Company (the "Information"). At all times, Information shall be deemed confidential and proprietary and subject to the restricted use of evaluating the business of the Company for the Purpose and distribution shall be prohibited, other than as provided herein.



“MyndMove takes the burden off patients, caregivers and the healthcare system, and more importantly improves the patient’s quality of life and ability to go out into the community...”

*Naaz Desai (Kapadia) PT, BSc PT, MSc, PhD, Post Doctoral Fellow
KREMBIL RESEARCH INSTITUTE-UHN*

ABOUT MyndTec

OUR MISSION

At MyndTec our mission is to improve the quality of human life by enabling people to do more, feel better and live independently, through innovation and utilization of technology and cost-effective access to care.



OUR VISION

- 1) Improve patient outcomes
- 2) Improve patient experience by minimizing disruption to their lives
- 3) Increase therapist & care team satisfaction
- 4) Improve ROIs for clinics & hospitals

ABOUT MyndTec

MyndTec is a medical device technology company focused on the treatment of Stroke and Spinal Cord Injury (SCI) and other brain related disorders. Our flagship product, MyndMove™ – is an advanced Functional Electrical Stimulation (FES) technology.

SERVICES

Rehabilitation for Stroke & SCI

- Upper limb focus

Functional Electrical Stimulation

- Restore movement and mobility

Unique Protocols

- Scientifically validated to improve movement outcomes

TECHNOLOGY

Device – MyndMove™

- FES therapeutic device
- 8 channels for stimulation

Software

- 30 algorithmic movement settings
- Therapist Interface capability

Data & Dashboard

- Identified Common Use Protocols (CUP) to optimize treatment outcomes.

DISTRIBUTION

3rd Party Distributors

- Focused on medical device solutions to therapists and clinicians

Direct Sales

- MyndTec in-house team

CHANNELS

Outpatient Rehab Facility (ORF)

- Hospitals & Private Rehab Clinics
- VA/DOD Government System

Inpatient Clinics

- Hospital Rehabilitation Clinics

Home Health Agency

- Occupational or Rehab home therapy

COMPETITIVE ADVANTAGES



MyndTec has built a solid foundation of advanced FES technology and critical corporate and technical infrastructure which act as key enablers in executing its growth strategy, adding scale and further capturing market share.

INFRASTRUCTURE & TECHNOLOGY

Commercialized Product

- FDA and Health Canada clearance received

Distribution Partnerships

- North American and Global
- Adding new partners

MyndMove™

- Flagship device
- Unique proprietary differentiation

Secured IP Rights

- Patents:
 - 11 owned
 - 8 exclusively licensed
 - 4 in license
- Applications:
 - 3 owned
 - 5 in license

Clinical Research Studies

- Supporting technology and patient outcome improvement

Home Use

- Regulatory clearance for use at home with a therapist

Relationship - KITE

- Access to KITE technology and innovation

Cloud Connected

- Data analytics, patient connected to therapist
- Ability to remotely change & optimize treatment

Clinical Experience

- Dozens of devices
- Hundreds of patients
- Thousands of sessions

Pipeline

- Lower Limb
- Depression

Data Driven Improvements


- Product enhancements
- Optimize treatment plans

WHAT IS FES

Functional Electrical Stimulation (FES) generates muscle contractions through electrical pulses. Treatment and therapy produces measurable functional movements such as reaching and grasping.

FES Therapy has three components:

- 1) **Patient** must be actively attempting a motor task.
- 2) **FES System** produces the intended movement which also generates the corresponding correct sensory feedback.
- 3) **Therapist** guides the limb in motion ensuring quality & correctness of movement.
 - Therapist also adjusts the stimulation according to the changes observed in the patient throughout rehabilitation



ABOUT MYNDTEC



MyndTec is dedicated to the development and commercialization of innovative products that improve function, maximize independence and enhance the quality of life for individuals who have suffered injury to the central nervous system as a result of stroke and spinal cord injuries (“SCI”).

MyndMove

- The first commercial product by MyndTec
- Non-invasive neuro and nervous system electrical stimulation therapeutic device
- Treating neurological diseases and injury
- Targeting markets with large, growing, global patient populations.



NEXT GENERATION FES & MyndMove®

High Tech Bioelectronic Device + Protocols + Therapy for Moderate to Severe **Neuro-muscular Symptoms**

MyndMove non-invasive therapy stimulates the brain to form and reorganize synaptic connections to increase neuromuscular functionality (“neuroplasticity”)

Approved commercial technology product that restores voluntary movement to stroke and SCI patients



- **Positive results in refractory cases**
(positive results in > 90% of stroke patients who have zero mobility, where other therapies have failed)
- **Non-invasive**
- **Good acceptance from patients**
(low discomfort and short sessions)
- **Reimbursable***
(FDA cleared; codes for reimbursement; third party payers)

**Reimbursable through a mixture of codes used to target therapist times vs treatment.*

Indicative MyndMove Breakthroughs

Establishing a true gold standard in the treatment of paralysis

Best-In-Class Non-Invasive Device	Benefits
<p>MyndMove offers the most diversity of grasping and/or reaching capabilities in patients including:</p> <div data-bbox="333 648 1082 839"><ul style="list-style-type: none">▪ Lateral Pinch▪ Palmar Grasp▪ Pinch Grasp▪ Lumbrical Grasp▪ Tripod Grasp▪ Varied Reaching Movements</div> <p>MyndMove includes patented technology that achieves functional muscle contractions at very low stimulation intensities</p> <div data-bbox="333 1051 1072 1228"><p>Fast slew rate and the ability to engage nerve fibers allows electrical pulses that are 10-15 times lower in intensity than those currently available products</p></div>	<ul style="list-style-type: none">✓ Activation of the intrinsic muscles of the hand✓ Ability to treat severe upper limb paralysis✓ Increase flexibility✓ Produce various fine motor distal movement✓ Help patients recover everyday capabilities<ul style="list-style-type: none">• Write, brush teeth, pick up objects, toileting✓ Suitable for stroke and spinal cord injury✓ Reduces intensity of stimulation✓ Reduces discomfort during stimulation✓ Patients effectively complete their therapy

VIDEO BEFORE & AFTER

World leading FES therapy - muscle stimulation through electric currents

- *Tolerable in contrast to traditional functional electrical stimulation*
- *Personalized treatment plans to solve enormous economic & quality of life burdens*
- *Real world objects and tasks training*


VIDEO: Before and After MyndMove Therapy



<https://youtu.be/Dct0e1tuxKA>

CLINICAL EVIDENCE - VOLUNTARY MOTION

Multiple studies demonstrate substantial improvement in voluntary movement over control cohort.



Upper extremity Fugl-Meyer (UE-FMA)

- All patients in the FES Therapy group realized a clinically significant gain in UE-FMA.

Median gain for the FES group was 24.5 pts.


Range as 9–48 pts.

- Only 2 of 11 patients (18%) in the Control group realized gains of more than 6 points.


Median gain for the Control Group was zero (0).

CLINICAL EVIDENCE – SIM SCORE

An indicative randomized control trial⁶ analyzed spinal cord independence measure (SCIM), a sub-score measuring an individual's ability to take care of themselves after spinal cord injury



■ Before ■ After



GROUP 1: received **80 hours** of therapies during an 8-week period

SCIM scores improved by an average of **3.2 points**

GROUP 2: received **40 hrs** of therapies incorporating MyndMove for 8-week period

SCIM scores improved by an average of **10.2 points**

*Min score (fully dependent): 0 , Max Score: (fully independent): 20

OUR PARTNERS



MyndTec Inc. has been fortunate to partner with a number of organizations, each of which have contributed to the development and commercialization of MyndMove™ therapy.



CURRENT TREATMENT LOCATIONS



MyndMove™ is licensed for use in Canada and the United States.

Therapy using the MyndMove™ device is delivered by highly trained physical and occupational therapists and also licensed or certified physical therapist assistants (PTAs) and occupational therapy assistants (OTAs) under their supervision.



MILESTONES & ACHIEVEMENTS

Highlights

Full Year 2021-22

MyndTec

Capital Markets:

- Listing on the CSE on February 24, 2022
- Ticker Symbol: MYTC

Technology & Partnerships:

- Signing of LBBAT distribution partnership agreement for the U.S
- Signing of strategic alliance with Fourier Intelligence for distribution in Asia
- Signing of exclusive supply and distribution agreement for the US and Canada with Guangzhou Longest Science and Technology Co Ltd. ("GLST") for distribution of MyndStep.

FDA Clearances and Listings:

- MyndTec Receives FDA 510(k) Clearance for MyndMove 2.0, its Second Generation Neuromodulation Device, for Clinical & Home Use
- MyndTec lists MyndStep in the FDA.

Strategic:

- 360° Review of:
 - Clients & Targets (Hospitals, Clinics, etc.)
 - Technology & Competitions Tech
 - Sales Process
 - Distribution Partners


STRATEGIC PLAN

3 Year Strategy

2022-2024

5 Pillars for Growth:

- Model
- Market
- Distribution
- Training
- Tech



REFINE BUSINESS MODEL

OBJECTIVE

Offer a solution to customers that meets both their selection criteria and procurement processes

APPROACH

LEVERAGE MYNDTEC'S CAPABILITY:


- Providing seamless experience - sales, review, technical and financial impact analysis, while meeting a prospect's selection criteria and procurement requirements.
- MyndTec is able to offer:
 - **Fee for Service – pay every time device is used**
 - **Direct Equipment Sale – one time purchase**

Target Market Criteria:

- MyndTec's target market is neurorehab clinics with a focus on patient treatment and research
- Active user in FES to enhance neuroplasticity
- Early adopters of technology

Understanding what drives adoption

Recognizing procurement policies, mandates & customer sensitivities



TARGET MARKET NEEDS



OBJECTIVE

Focus MyndTec's market penetration efforts on the gatekeepers – therapists, by addressing their challenges and needs (TTR)

FEEDBACK SUMMARY

Therapist Challenges:

- Ease of use: Electrode set-up time and complexity
- Complicated Protocols: bottleneck and delays
- Productivity: get patients in and out quickly, without compromising quality of treatment

} **Time,
Turns &
ROI**

Required to Enable MyndTec to gain market traction:

Best
Performing
Clinics

Data Collection
Improvements

Adjusted
Training

APPROACH

“It is not enough that the patient likes using MyndMove™ and is seeing results.”

Remain focused on the patient experience:

- Efficacy of our system
- Evidence of steady improvement
- Measurable outcomes
- Improved quality of life for the patient.

First experience with MyndMove™ is critical for adoption.

Starts with easy protocols, quick setup, intensive hands-on training.

MyndMove™ DASHBOARD

← Patient

1000467
ID

Name

M

Gender

15 September 1961

Date of Birth

(Blank)

Injury Date

Practice

17-Jun-2019


First Session

04-Oct-2021

Last Session

101


Total Sessions



Protocols

Select all Bilateral Left Other Right

Protocol Name	Runs	Cycles
R04: (L) Forward Reach	57	2180
R01: (L) Hand - Mouth	23	565
R08: (L) Scapular Rotation > Forward Reach	16	584
R03: (L) Side Reach	14	354
G01: (a) (L) Finger Ext. > Palmar Grasp	11	378
G05: (a) (L) Finger Ext. > Lumbrical + Palmar	6	267
R02: (L) Opposite Shoulder Reach	3	45
R05: (L) Opposite Shoulder + Lateral Reach	3	121
R04: (R) Forward Reach	2	98
C05: (L) Forward Reach + Palmar Grasp	1	18
G01: (a) (R) Finger Ext. > Palmar Grasp	1	15
G06: (a) (R) Finger Ext. > Lateral Pinch	1	12
G11: (L) Finger Ext. > Tripod Grasp	1	29
Total	139	4666



REVAMP TRAINING PRACTICES

Simplify and improve current training practices

Establish a less intimidating method of training, and avoid “straight to complexity” set-up and protocol education

FEEDBACK SUMMARY

- Onboarding, training and time commitment must be shortened.
 - hours vs days
 - online vs live
- Set-up and training proficiency in a phased manner – less intimidating (baby steps)
 - 3 electrodes & 2 protocols
 - 4 electrodes & 3 protocols

ONBOARDING PRIORITIES

- Our goal is smooth onboarding experience
- Easy set-up
- Focused on quality of treatment
- Ensure a very positive first experience

Be a trusted resource on FES and provider of choice for leading Hospitals, Clinics and the Therapist Community

ESTABLISH SALES & DISTRIBUTION



3 Key Focus Areas of MyndTec's Sales Strategy

ENGAGE 3rd PARTY DISTRIBUTORS

- Agent model offers low capex expansion
- Maximize access to target market in multiple jurisdictions and channels:
 - Rehab Clinics
 - VA Clinics
 - Hospital Networks
 - Home Care
 - University Research Centers

SELECTIVE REGIONAL EXPANSION

Build out high profile locations in select top North American markets:

- Michigan
- Ohio
- Massachusetts
- Illinois
- Select Canadian cities
- Virginia


GROW GLOBAL DISTRIBUTION NETWORK

- Establish relationships with leading
 - global health care networks,
 - medical device distributors,
 - technology focused care/rehabilitation partners
- Target leaders in their markets

Build a cost effective distribution platform, to expand MyndTec's presence in the US & Canada, while partnering with leading global networks

DISTRIBUTION MODEL OVERVIEW

Pilot-to-Commercial Partnership Model



GLOBAL DISTRIBUTION PARTNERSHIP



Fourier Intelligence Inks Strategic Alliance Partnership with MyndTec Inc.

March 23, 2022

The award-winning Canadian MyndMove™ therapy from MyndTec Inc joins SoftBank-backed rehab robotics leader Fourier Intelligence's network of partners

Fourier
Intelligence™

SoftBank
Group

Prosperity7
AN ARAMCO VENTURES FUND

Vision Capital

IDG Capital



This partnership will focus on the distribution of MyndMove™, a non-invasive functional electrical stimulation-based intervention, to the ever-expanding global network of Fourier Intelligence.

Fourier's global network spans over 50 countries to ensure a broad market outreach for innovative technologies. With joint laboratories with some of the top research institutes in the world such as ETH Zürich, University of Melbourne, and Shirley Ryan AbilityLab in Chicago, Fourier is set to chart the new frontier of innovative medical technologies.

“Our partnership with MyndTec Inc. signifies yet another successful strategic collaboration with market leaders to offer innovative and clinically effective technology for our patients globally,” said Zen Koh, Co-Founder and Global HQ CEO of Fourier Intelligence. “MyndMove™, an electrical stimulation-based intervention, integrates perfectly into Fourier’s RehabHub™ solution and complement our existing product/technology portfolio. Fourier will continue our investment into more of such joint technological developments to better provide highly integrated intelligent rehabilitation technologies to empower clinicians and patients.”

US DISTRIBUTION PARTNERSHIP



MyndTec Enters In Exclusive Distribution Agreement with LBB Applied Technology (LBBAT)

September 29, 2021

LBBAT has the exclusive right to market and distribute the MyndMove™ device:

1. in the State of Michigan;
2. to all healthcare facilities operating in the State of Michigan; the VA Polytrauma Rehabilitation Centers and the Polytrauma Transitional Rehabilitation Center Programs located in Palo Alto, CA; San Antonio, TX; Minneapolis, MN; Richmond, VA; and Tampa, FL; the Walter Reed National Military Medical Center in Bethesda, MD; the Ascension Hospital System;
3. any additional hospital systems the parties may agree (the "Exclusive Customers")

About LBB

Life Beyond Barriers Applied Technology is a division of Life Beyond Barriers Rehabilitation Group, which operates two outpatient rehabilitation facilities in Michigan. The clinics utilize leading technology as part of their patient therapy and were early adopters and high users of MyndMove™.

MyndMove™ Approved by Veteran Affairs Hospital Network Supplier List

October 1, 2021

Completed and successfully received certification


Vetted, reviewed and approved as trusted supplier of medical device to Veteran Affairs health networks.

With 9 million veterans to serve, the VA is the largest healthcare system in the U.S. and is comprised of hundreds of hospitals, medical centers, clinics and more

Offers opportunity and access to leading, high profile, innovative clinics focused on Veterans Health:

Reestablish innovation as a core principal focus

Derisk and lessen the dependence of Company on MyndMove™, and diversify into additional revenue streams



Innovation can expand MyndTec's offering, add new and diverse potential sources of revenue and allow new growth opportunities

EXPAND PORTFOLIO – LICENSING

Actively exploring numerous highly effective and complementary technologies available from reputable global groups.

Primary Opportunities of Focus:

- Wearable garments with embedded sensors
- Dry electrodes for integration into garments
- Hand and arm mobility

Areas of Interest for FES:

- Major Depression Disorder
- Peripheral Artery Disease (PAD)
- Stem Cell and Regenerative Medicine



NEW FES DEVICE – LOWER BODY



Introducing MyndStep™

MyndStep™ is intended to provide ankle dorsiflexion of the foot and/or knee flexion, also improving an individual's gait or ability to walk.

MyndStep™ prevents or retards disuse atrophy, maintains or increases joint range of motion and local blood flow.

Device Advantage and Convenience:




- Easy Electrode Placement
- Wearable, Lightweight Design
- Mobile Phone & Tablet Friendly
- iOS or Google Play App Functionality with Easy User Control
- Variable Treatment Modes (Training & Walking)
- Adjustable Electric Stimulation Intensity
- Built-in Smart Sensors
- Rechargeable, long-lasting Li battery, USB charging
- For home and outdoor use

MyndStep
Foot Drop System



*Available across the United States and Canada,
since October 2022.*

FOOT DROP DEVICE COMPETITION

			
Model	MyndStep	L300 Go / Bioness	Walkaide / Innov. Neurotronics
Price	\$1,000	~ \$6,000	~ \$5,000
Weight	60g	60g	87.6 g
Dimension	59x59x22 mm3	82x47x15 mm3	61x83x20.5 mm3
Battery	1200mAh, Rechargeable	1000mAh, Rechargeable	Four 1.5 Volt Alkaline AA, LR6
Mode	Train, Walk	Training, Gait, Clinician	Walk (Heel, Hand or Tilt)
Intensity	0-100mA, Increment of 1	0-100mA, Increment of 1	0-121mA
Duration	50-500μs, Increment of 10	250-1250μs, 8 Levels	25-300 μs. 7 levels
Frequency	10-80Hz, Increment of 1	10-45Hz, Increment of 5	16.7-33.3 Hz Increment of 5 to 8
Output Waveform	Symmetric Biphasic Pulse	Asymmetric/ Symmetric Biphasic Pulse	Biphasic Asymmetrical Pulse
Control	App & Device	Remote & Device	App & Device

FOOT DROP – MARKET DYNAMICS

Foot Drop Market:

- North America represents major market share in the global foot drop treatment market due to the high prevalence of stroke
- Stroke causes upper motor neuron injuries that lead to foot drop, an inability to lift the forefoot due to the weakness of dorsiflexors of the foot.
- Functional electric stimulation (“FES”) segment is expected to dominate the market growth
- More than 70% of hemiplegic stroke patients who can regain walking ability although they do not achieve good gait, **can take advantage of a treatment such as MyndStep™**, designed to help patients to recover their gait and correct their foot drop ailment.

Source:

(1) Mordor Intelligence: Foot Drop Treatment Market, Growth, Trends, Covid-19 Impact and Forecasts (2022-2027)

(2) (6) <https://www.researchandmarkets.com/reports/5529412/foot-drop-treatment-market-growth-trends>

795,000

people experience stroke every year in the United States⁽¹⁾

9.5%

in foot drop compound annual growth rate (CAGR) forecast⁽²⁾

US & Canada

representing one of the largest foot drop markets⁽¹⁾

COMPETITIVE LANDSCAPE

NAME	SYMBOL	MARKET CAP	SALES
NeuroMetrix Inc.	NURO	US \$28M	US \$8.4M
ReWalk Robotics Ltd.	RWLK	US \$62M	US \$5.5M
APYX Medical	APYX	US \$280M	US \$52M
Zynex Inc.	ZYXI	US \$283M	US \$137M
Inspire Medical Systems Inc.	INSP	US \$4.5B	US \$62M
iRhythm Technologies Inc.	IRTC	US \$4.0B	US \$202M

COMPETITIVE LANDSCAPE



NeuroMetrix Inc.

Ticker: NURO

Market Cap: \$28M

Sales: \$8.4M



Core Product: DPNCheck®

Other: ADVANCETM System, Quell®

Sales Model: In-house and 3rd Party

ReWalk Robotics Ltd.

Ticker: RWLK

Market Cap \$62M

Sales: \$5.5M



Core Product: ReWalk™ Personal 6.0

Other: The ReStore™ Soft Exo-Suit

Sales Model: In-house and 3rd Party

APYX Medical

Ticker: APYX

Market Cap: \$280M

Sales: \$52M



Core Product: Renuvion®

Other: J-Plasma®, Cool-Coag

Sales Model: In-house and 3rd Party

Zynex Inc.

Ticker: ZYXI

Market Cap: \$283M

Sales: \$137M



Core Product: NextWave

Other: NeuroMove, InWave, Patient Monitoring

Sales Model: In-house and 3rd Party

Inspire Medical Systems Inc

Ticker: INSP

Market Cap: \$4.5B

Sales: \$262M



Core Product: Inspire

Sales Model: In-house, Hospitals and Direct-to-consumer

iRhythm Technologies Inc.

Ticker: IRTC

Market Cap: \$4B

Sales: \$341M



Core Product: Zio Service

Other: Zio AT XT


Sales Model: In-house

EXPAND PORTFOLIO – KITE DEVELOPMENT



The KITE Research Institute  UHN

The research arm of the Toronto Rehabilitation Institute, KITE is a world leader in complex rehabilitation science and is dedicated to improving the lives of people living with the effects of disability, illness and aging.



MyndTec and Kite Collaboration:

- UHN Master Collaboration Agreement, the Company will sponsor, fund or collaborate with KITE for the research, development, testing and commercialization of FES technology
- We intend to work directly with KITE to develop new treatments, devices and products
- The Company and KITE are collaborating on an improvement to MyndMove™ to support the addition of protocols related to the treatment of lower limbs with a focus on regaining the ability to walk independently.
- Multimodal electrodes for neural precursor activation to promote neural regeneration
- Dry Electrodes for wearable garments to improve set-up time and for home use
- FES for Major Depressive Disorder (MDD)

EXPAND PORTFOLIO – M&A

Identify Leading Niche Technologies

TARGET PROFILE

- Geographic Location
 - Prefer Regional US, Canada, open to Global opportunities
- Niche, complementary device tech
 - FES Therapy
 - Used for Rehabilitation
 - Home or Clinic

CHARACTERISTICS

- Similar or smaller than MYTC
- Typically family owned, owner operated
- Requiring exit or liquidity event
- Some annual revenue \$100k – \$400k
- Growing Business with interesting growth and synergy opportunities

PREFERRED DEAL STRUCTURE

- Leverage being a Pubco
- Typical structure:
 - 1/3 Cash,
 - 1/3 Stock,
 - 1/3 Earnout (2- 3 year)
 - 3 – 6X TTM EBITDA

Active acquisition pipeline of 3+ potential targets.

CORE STRENGTHS

MyndTec Focus: Be the preferred provider of neurotechnology solutions tailored to improving patient outcomes and therapist satisfaction.



Execute on a clearly outlined and strategic growth plan and translate that success into unit sales growth and significant share price appreciation.

Key intellectual property rights secured in the areas of:

- Functional Electrical Stimulation (FES) Therapy
- Brain Computer Interface
- Neural Regeneration - Stem Cell and FES Integrated Therapy

Patent portfolio:

- Patents: 11 owned; 8 exclusively licensed; 4 in license discussions
- Applications: 3 owned; 5 in license discussions

Functional Electrical Stimulation (FES) Therapy - General Rehabilitation and Depression

- Functional Electrical Stimulation System with Pulse Control (Owned; 7 patents)
- Method for Functional Electrical Stimulation Therapy (Owned; 2 patents; 3 applications)
- Functional Electrical Stimulation Device and System, and Use Thereof (Licensed; 8 patents)
- Functional Electrical Stimulation Method, use and Apparatus for Mood Alteration (License discussions; 1 patent)

Brain Computer Interface

- Wireless Implantable Data Communication System, Method and Sensing Device (Owned; 2 patents)
- Method and System for Brain Activity Signal-based Treatment and/or Control of User Devices (License discussions; 1 patent; 5 applications)

Neural regeneration - stem cell and FES integrated therapy

Selective, Directable Electrotaxis of Precursor Cells with Biphasic Electrical Stimulation (License discussions; 2 patents)

CAPITAL STRUCTURE



CAPITALIZATION INFO (JULY 01, 2022)

Stock Symbol	MYTC
Share Price	\$0.95 (June 15, 2022)
Market Capitalization	CAD \$21M
Common Shares	21.8M
- Warrants	6.0M
- Options	0.98M
Fully Diluted Outstanding	28.8M

OWNERSHIP

Insiders & Significant		
Shareholders (Held in Escrow)	12.3M	56%
Retail Investors (FLOAT)	<u>9.5M</u>	<u>44%</u>
Total:	21.8M	100%

LEADERSHIP

Craig Leon – Chief Executive Officer

Scott Franklin– Chief Financial Officer

Ronald Kurtz – Vice-President, Engineering

Yesmil Pena - Quality Assurance Manager

BOARD OF DIRECTORS

Dr. Milos R. Popovic PhD - Interim Chairman

Dr. Harvey Griggs - Director

Richard Widgren - Director

William (Bill) Jackson – Director

Craig Leon - Director

CONTACT INFORMATION

MyndTec

CSE: MYTC

MyndTec Inc. Head Office:

1900 Minnesota Court, Suite 122

Mississauga, ON, CANADA

L5N 3C9

For further information visit:

www.myndtec.com

Craig Leon | CEO

craig.leon@myndtec.com

Bill Mitoulas | Investor Relations

billm@venturenorthcapital.com